Business Wire

ESI-GROUP

22.9.2021 14:26:12 CEST | Business Wire | Press release

Share
ESI Group: EMPHYSIS – The Missing Link Between Digital Simulation and Embedded Software

Regulatory News:

ESI Group (Paris:ESI):

The research project EMPHYSIS led by Bosch has delivered the new “eFMI standard” for model exchange to accelerate the model-based development of embedded software. On the 15th of September, this international collaborative project gathering 25 industrial and academic partners from different fields (like automotive and information technologies) situated in Belgium, Canada, France, Germany, and Sweden received the ITEA Award of Excellence for this unique achievement.

Better code with less effort through “eFMI” - the new model-exchange standard for embedded devices

When developing a new function, many engineers learn the hard way that their outstanding knowledge about the physics of their products is not enough by far to develop a function for an embedded target, due to the demanding requirements of safety-critical software, weak CPU magnitude and less memory than expected. While this might result in a never-to-be-realised excellent initial idea of operating and controlling their product in a much smarter way, at the same time it reveals the need for a link between digital simulation of physical processes and embedded software.

The aim of the EMPHYSIS project (Embedded Systems with Physical Models in the Production Code Software), led by Bosch, was to jointly come up with a new open standard that lays the foundation to develop new innovative tools. This that allows model-based functions to be realized directly in embedded software with better code and less effort. For this purpose, the project carried forward the idea of the very successful Functional Mock-up Interface (FMI) model exchange standard for simulation to develop FMI for embedded systems - the new “eFMI standard”. This enables a wide variety of advanced model-based approaches for control and diagnosis, such as solving a set of differential equations to compute a signal instead of measuring it via a sensor. By allowing a hardware sensor to be replaced with a piece of software, we significantly reduce the total cost.

« The EMPHYSIS project has achieved several outstanding results such as the automatic generation of efficient code for embedded devices. It shows the power of collaborative research projects to drive the adoption of a new standard and to generate significant productivity gains for the industry. »

– Jean-François Lavignon, ITEA Vice-chairman

The technical deep dive and benefits

Technically speaking, eFMI is innovative in that it provides a target-independent intermediate format defined by an entirely new language, the Guarded Algorithmic Language for Embedded Control: GALEC. This new programming language is able to guarantee that an algorithm described in this language can be translated into code that has:

  • static worst-case execution time;
  • static a-priori known memory demand; and
  • a statically proven absence of illegal memory access.

In other words: code that satisfies the hard requirements of automotive safety-critical embedded software, which also makes it applicable to many more, less restricted domains like robotics, industrial applications and consumer goods.

With eFMI and GALEC it is now possible to capture the computational essence of a model in a target-independent form that is a solid foundation for any code generator to produce highly optimised code for arbitrary runtime environments and software architectures. All this is cast into a traceable, extendable and verifiable container architecture that goes far beyond a simple exchange format.

The eFMI workflow allows developers to model a system on a higher level of abstraction, starting with a reusable, high-level, component-oriented and physically structured model. The tooling kit then automatically transforms this into a solution which can be better integrated into software.

The main benefits of this solution and the associated eFMI workflow are:

  • accelerating development time;
  • better use of domain experts by separating the concerns of physical modelling and embedded implementation;
  • overcoming vendor lock-in through eFMI being published as an open standard on GitHub; and
  • enabling new ways of OEM supplier collaborations.

Continuous success

An OEM Advisory Board has been established to gather additional requirements, input and use-cases and further disseminate the project’s results, helping to secure uptake and future innovations in new domains.

On 22 March 2021, right after the project’s end, the non-profit Modelica Association officially approved a new project under its umbrella to further develop, standardize and promote eFMI. With Robert Bosch GmbH, Dassault Systèmes, DLR Institute of System Dynamics and Control, dSPACE, ESI Group, ETAS GmbH and Modelon AB as initial members of the steering committee and Mercedes-Benz AG having joined recently, the first official release of eFMI 1.0 is targeted within 2021. Having developed 14 tools within EMPHYSIS, eFMI already has a broad foundation even before its official release.

« What makes us proud as a team is the fact that this success has been recognized not only by our business partners and the OEM Advisory Board representing the voice of the customer, but also by the ITEA organization.»

– Oliver Lenord, Research Engineer at the Model-based Systems Engineering department at Robert Bosch

For society as a whole, EMPHYSIS’ better software translates into safer and more efficient vehicles which are able to keep pace with customer demands and help tackle climate issues in the longer term. For the time being, however, the project’s message is clear: by taking full advantage of an equation-based, component-oriented modelling language with a good library, 90% gains can be made in productivity of model-based function development.

EMPHYSIS project partners

Belgium

  • Dana Belgium
  • Siemens Industry Software NV
  • University of Antwerp NEXOR

Canada

  • Maplesoft

France

  • CEA
  • Dassault Systemes SE
  • FH Electronics
  • Institut Polytechnique de Grenoble
  • OSE Engineering
  • Renault SAS
  • Siemens Industry Software SAS
  • SOBEN

Germany

  • AbsInt Angewandte Informatik GmbH
  • Deutsches Zentrum für Luft- und Raumfahrt (DLR) System Dynamics and Control
  • dSPACE GmbH
  • Elektronische Fahrwerksysteme GmbH
  • ESI ITI GmbH, part of ESI Group
  • ETAS GmbH
  • PIKETEC
  • Robert Bosch GmbH

Sweden

  • Dassault Systèmes AB
  • Linköping University
  • Modelon AB
  • RISE - Research institutes of Sweden SICS East
  • Volvo Personvagnar AB

About ITEA

ITEA is the Eureka Cluster for software innovation, enabling a large international community to collaborate in funded projects that turn innovative ideas into new businesses, jobs, economic growth and benefits for society. https://itea4.org

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information: https://www.esi-group.com/fr .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye